The Daily Beast | January 13, 2022
“Putting it in the hands of the postal service is a risk,” said Lawrence Gostin, director of the O’Neill Institute for National and Global Health Law at Georgetown Law Center, who bluntly told The Daily Beast that the mail carrier is “just ill equipped” to deal with sensitive pharmaceutical tests on a mass scale.